Abstract
The deep lungs provide an efficient pathway for drugs to transport into the systemic circulation, as the extremely large surface area and thin epithelial membrane enable rapid drug transport to the blood stream. To penetrate into the deep lungs, aerosol particles with aerodynamic diameters of 1-3 m are optimal. Large porous hollow particles (LPHPs) can achieve this aerodynamic size range through enhanced porosity within the particles (typically < 0.4 g/cm3), which aerodynamically balances the large particle size (> 5 µm, up to 30 µm). The physical properties of these particles provide some key advantages compared to their small, nonporous counterparts through enhanced dispersibility, efficient deep lung deposition, and avoidance of phagocytic clearance. This review highlights the potential of LPHPs in pulmonary delivery of systemic drugs, with a focus on their critical attributes and key formulation aspects. In addition, three examples of LPHPs under development are presented to emphasize the potential of this technology to treat systemic diseases.
Keywords: PulmoSpheres, nanoparticle aggregates, porosity, dispersibility, aerodynamic diameter, systemic circulation.
Current Pharmaceutical Design
Title:Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery
Volume: 22 Issue: 17
Author(s): Sachin Gharse and Jennifer Fiegel
Affiliation:
Keywords: PulmoSpheres, nanoparticle aggregates, porosity, dispersibility, aerodynamic diameter, systemic circulation.
Abstract: The deep lungs provide an efficient pathway for drugs to transport into the systemic circulation, as the extremely large surface area and thin epithelial membrane enable rapid drug transport to the blood stream. To penetrate into the deep lungs, aerosol particles with aerodynamic diameters of 1-3 m are optimal. Large porous hollow particles (LPHPs) can achieve this aerodynamic size range through enhanced porosity within the particles (typically < 0.4 g/cm3), which aerodynamically balances the large particle size (> 5 µm, up to 30 µm). The physical properties of these particles provide some key advantages compared to their small, nonporous counterparts through enhanced dispersibility, efficient deep lung deposition, and avoidance of phagocytic clearance. This review highlights the potential of LPHPs in pulmonary delivery of systemic drugs, with a focus on their critical attributes and key formulation aspects. In addition, three examples of LPHPs under development are presented to emphasize the potential of this technology to treat systemic diseases.
Export Options
About this article
Cite this article as:
Gharse Sachin and Fiegel Jennifer, Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery, Current Pharmaceutical Design 2016; 22 (17) . https://dx.doi.org/10.2174/1381612822666160128145356
DOI https://dx.doi.org/10.2174/1381612822666160128145356 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Perspectives on the Tertiary Prevention Strategy for Alzheimer’s Disease
Current Alzheimer Research Somatic Drugs for Psychiatric Diseases: Aspirin or Simvastatin for Depression?
Current Neuropharmacology Multiple Drug Targets in the Management of Type 2 Diabetes
Current Drug Targets Proteomic Analysis of the Kidney in Rat Biliary Cirrhosis
Current Proteomics Cell Cycle Inhibition in Malignant Lymphoma: Disease Control by Attacking the Cellular Proliferation Machinery
Current Drug Targets T-type Calcium Channels in Health and Disease
Current Medicinal Chemistry Neurochemical and Neuropharmacological Aspects of Circadian Disruptions: An Introduction to Asynchronization
Current Neuropharmacology Follicular Immunology Environment and the Influence on In Vitro Fertilization Outcome
Current Women`s Health Reviews Determining and Overcoming Resistance to HIV Protease Inhibitors
Current Drug Targets - Infectious Disorders HIV-1 Reverse Transcriptase: A Therapeutical Target in the Spotlight
Current Medicinal Chemistry Therapeutic Potential of Peptide Toxins that Target Ion Channels
Inflammation & Allergy - Drug Targets (Discontinued) Transdermal Oxandrolone: Ex Vivo Percutaneous Absorption Study
Current Drug Delivery Rationalizing the Study of Plants for the Treatment of Oral Pain
Current Chemical Biology Long Chain Omega-3 Polyunsaturated Fatty Acids in Pediatric Metabolic Syndrome
Mini-Reviews in Medicinal Chemistry The Relevance of Peripheral Immune Tolerance in Normal Pregnancy and its Potential Failure in Gestation-Associated Diseases
Current Women`s Health Reviews Pathogenesis and Treatment of Secondary Hyperparathyroidism in Dialysis Patients: The Role of Paricalcitol
Current Vascular Pharmacology Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Protein Aggregation and Defective RNA Metabolism as Mechanisms for Motor Neuron Damage
CNS & Neurological Disorders - Drug Targets G Protein-Coupled Receptors in Regulation of Body Weight
CNS & Neurological Disorders - Drug Targets Leptin- and Leptin Receptor-Deficient Rodent Models: Relevance for Human Type 2 Diabetes
Current Diabetes Reviews